Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Health Canada Approves XEOMIN® for Post-stroke Spasticity Treatment in Adults
Details : Xeomin (Incobotulinumtoxin A) is a SNAP25 inhibitor drug candidate, which is approved and indicated for the treatment of post-stroke lower limb spasticity involving the ankle and foot in adults.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
December 17, 2024
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vensica Medical Secures $11M for Overactive Bladder Phase 2 Trials
Details : The fund will support the company's mid-stage clinical trials for its revolutionary treatment of overactive bladder using Xeomin (Incobotulinumtoxin A), delivered through a needle-free device.
Product Name : Xeomin
Product Type : Large molecule
Upfront Cash : Undisclosed
October 28, 2024
LOOKING FOR A SUPPLIER?
Reset All
